For laboratory research use only · Not for human or veterinary use · 18+
Metabolic research

Buy Retatrutide Pen in Australia

Pre-filled pen, 15mg · Available to order, dispatched from Australia
Choose strength: 15 MG
$229.99

Buy Retatrutide pen stock in Australia from Macropus Peptides in four pre-filled strengths: 15mg, 20mg, 30mg and 70mg. Each Retatrutide pen arrives with the peptide already in solution inside a sealed cartridge, so there is no powder to dissolve and no diluent to measure before laboratory work begins. The label on every pen gives compound, total amount, lot number and storage temperature, and a certificate of analysis is available for each lot on request. Pens must be kept refrigerated at 2 to 8 degrees Celsius and never frozen. Pen needles are sold separately, and the 20mg and 30mg strengths are also offered as pen kits. The 70mg pen carries the lowest cost per milligram of any pen strength and keeps a long study on one lot. Order a Retatrutide pen online and it is dispatched from local Australian stock to any Australian address. Sold to researchers aged 18 and over for in-vitro laboratory research only, never for human or veterinary use.

1
Frequently bought together
For in-vitro laboratory research only. Not for human or veterinary use. Purchasers must be 18 or over.
CompoundRetatrutide pen
Amount15 mg
FormPre-filled pen, solution
CategoryMetabolic research
Storage2 to 8 °C, do not freeze
TestingHPLC purity 98% or higher and mass spectrometry identity, every batch
Certificate of analysisAvailable for every lot, matched to the lot number on the label

Buy Retatrutide Pen Australia: 15mg, 20mg, 30mg and 70mg Pre-Filled Pens

Macropus Peptides supplies the triple agonist in a second format alongside our freeze-dried vials: a pre-filled pen that holds the peptide ready dissolved. Four strengths are stocked, 15mg, 20mg, 30mg and 70mg, and every pen is lot-released out of the stock that also fills our powder vials. The pens suit laboratories that would rather receive a finished solution than prepare one, and the vial range remains available for groups who prefer to set their own concentration.

Retatrutide pen Australia: what the peptide is

Inside every cartridge is the same synthetic peptide sold in our vials, known during development by the code LY3437943. It was designed for metabolic research as one molecule that activates three receptors at once: those for GLP-1, GIP and glucagon. Older compounds in the class reach a single receptor, or two in the case of the dual agonists, so it is usually described as a triple agonist. The molecule is still investigational. Its phase 3 programme is running overseas, no Australian regulator has assessed it, and the only lawful supply here is research material such as these pens.

How Retatrutide works in research

GIP and GLP-1 are gut hormones that amplify insulin release when glucose is raised, and GLP-1 also slows gastric emptying. Glucagon acts mainly on the liver, where it raises glucose output and fat oxidation. Researchers use the molecule to ask what happens when all three pathways are engaged together, and in particular what the glucagon arm adds compared with dual GIP and GLP-1 agonists. Binding to albumin through an attached fatty acid chain slows its clearance and stretches its half-life, while modified residues protect it from the enzymes that clear native gut hormones within minutes.

Retatrutide clinical trials and the published record

The peptide was first described, with its receptor potency and early human pharmacology, in Cell Metabolism in 2022. A phase 1b trial in type 2 diabetes followed in The Lancet that year. In 2023 two phase 2 papers followed: an obesity trial published by the New England Journal of Medicine and a type 2 diabetes trial in The Lancet, each tracking body weight, glycaemic markers and safety. Liver fat was the endpoint of a phase 2a study reported in Nature Medicine in 2024. None of this work concerns the pen as a format; it is the record for the molecule itself, summarised with designs and measured endpoints in our Retatrutide research studies library.

Retatrutide pen specifications and cold storage

SpecificationDetail
CompoundRetatrutide pen
Amount15 mg
FormPre-filled pen, solution
CategoryMetabolic research
Storage2 to 8 °C, do not freeze

A pre-filled pen is a sealed glass cartridge of peptide solution fitted inside a dial pen body. The solution is made up, filtered and filled before labelling, so the total printed on the pen (15, 20, 30 or 70 milligrams) is already in liquid form. Fill volume and resulting concentration are printed on each pen and repeated in the analysis certificate for its lot, and those two figures are the reference when planning how solution is drawn at the bench. The body is single use and is never refilled. Each label also gives the compound name, the lot number and the storage instruction, and the printed lot code is what we match your certificate to. Because the peptide is dissolved rather than dry, cold chain matters more than it does for powder: hold every pen at 2 to 8 degrees in darkness and never let it freeze, since ice can damage both the cartridge seal and the peptide.

Retatrutide pen price in Australia

StrengthPricePrice per mg
Retatrutide pen 15mg$229.99$15.33 per mg
Retatrutide pen 20mg$289.99$14.50 per mg
Retatrutide pen 30mg$399.99$13.33 per mg
Retatrutide pen 70mg$729.99$10.43 per mg

Pen prices are set in Australian dollars strength by strength, and the cost per milligram drops as the total amount rises, from the 15mg pen at the top to the 70mg pen at the bottom. Milligram for milligram, a pen costs somewhat more than the matching freeze-dried vial, reflecting the extra steps of making up, filling and cold handling the solution.

Retatrutide 15mg pen: the entry strength to order first

The 15mg pen is the entry strength and the one most often ordered to trial the format. It holds enough material to validate a handling method and an assay on a single lot before a laboratory commits to a larger pen. Buyers comparing formats often order it beside a 15mg vial to see which workflow fits their bench.

Retatrutide 20mg pen: a mid-size strength, also sold as a kit

The 20mg pen adds a third more peptide than the 15mg and brings the cost per milligram down. It is also sold as the 20mg pen kit, which pairs the pen with 20 pen needles and 20 alcohol swabs and is priced below the pen on its own, making the kit the smarter purchase at this strength.

Retatrutide 30mg pen: for established protocols

Twice the content of the 15mg pen, the 30mg strength suits a protocol that is already settled and needs a longer run from one cartridge. A matching 30mg pen kit with needles and swabs is available and, as with the 20mg strength, costs less than the pen alone.

Retatrutide 70mg pen: the largest in the range

With more than double the content of our biggest powder vial, the 70mg pen is also the cheapest pen per milligram. It is chosen for long or multi-arm work where every sample must come from one lot, since a change of lot midway adds a variable that has to be controlled for.

Where to buy Retatrutide pens in Australia

  • Sold online at macropuspeptides.com in 15mg, 20mg, 30mg and 70mg, priced from $229.99
  • Every batch HPLC tested to 98% or higher purity, with identity confirmed by mass spectrometry
  • A certificate of analysis for every lot, matched to the lot number printed on the label
  • Same-day dispatch from Australian stock for orders paid before 2pm AEST on a business day
  • Tracked delivery Australia wide: standard in 2 to 5 working days, express in 1 to 2 working days
  • Payment by PayID or bank transfer, with your order ID as the reference

How to get Retatrutide pens: ordering online

  • Pick the 15mg, 20mg, 30mg or 70mg pen, or one of the pen kits
  • Add 32G 4mm pen needles if you are buying a pen on its own
  • Enter the quantity and review the cart
  • Pay at checkout and declare that you are an adult researcher
  • Refrigerate the pens as soon as the parcel arrives and request your lot certificate

How to store Retatrutide pens: what replaces reconstitution

The pen takes reconstitution out of the workflow. There is no diluent to choose, no volume to calculate and no chance of a mixing error shifting the concentration between operators, so a group repeating one assay over several weeks starts from an identical solution every time. The sealed cartridge also limits how often the solution meets air. What the format asks for in return is disciplined cold handling. Move pens into refrigeration at 2 to 8 degrees the moment the parcel is opened, leave each in its carton out of the light, and return each one to the cold as soon as it has been handled. Mark the date a pen was first opened and log its lot with every data set. A pen that has frozen, or sat warm for hours, should be replaced rather than used for data. The freeze-dried Retatrutide vials remain the better buy when cost per milligram matters most, when reserve stock must sit frozen at minus 20 degrees for months, or when a study needs a concentration other than the filled one.

Is Retatrutide available in Australia

Only as research material. The ARTG carries no entry for it, and the TGA has neither evaluated nor approved it, so neither the pen nor the vial may be supplied for therapeutic purposes or used on humans or animals. The phase 3 programme overseas has not yet concluded. Before ordering, look up which Poisons Standard schedule covers this peptide for your institution.

Retatrutide pens for sale Australia wide, packed cold

Pens leave our Australian stock in cold packaging for Hobart, Darwin, the other capitals and regional towns, and no customs step slows them down. Groups building a wider metabolic panel often add Cagrilintide or Tirzepatide, and the full selection is in our metabolic research range.

References

  1. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism. 2022.
  2. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet. 2022.
  3. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine. 2023.
  4. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024.

Scientific content compiled from the peer-reviewed literature above by the Macropus Peptides technical team. Information is provided for research reference only.

Questions about Retatrutide pen

Chat on WhatsApp
Retatrutide pen 15mg$229.99